Regen BioPharma Inc. is a publicly traded biotechnology company trades under the symbol RGBP on the OTC Bulletin Board and OTC PINK markets. Regen is focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Regen BioPharma identifies 30 promising technologies for rapid commercialization
Narrowed from a review of more than 20,000 US issued patents covering stem cell related matter, Regen BioPharma us in negotiations to license several patents for cell therapy products...
Regen BioPharma Inc. trades under the symbol
RGBP on the OTC Bulletin Board and OTC PINK markets. Regen is a biotechnology company focused on...
SAN DIEGO, CA, Dec 11, 2014
(Marketwired via COMTEX) -- Regen BioPharma Inc.
(OTC PINK: RGBP) announced today it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and ...